#### "EXPRESS MAIL CERTIFICATE" "EXPRESS MAIL" MAILING LABEL NUMBER EV332944733US **DATE OF DEPOSIT December 8, 2003**

Attorney Docket No. P31853C2

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Buckingham, et al.

December 8, 2003

Serial No.:

Not Yet Assigned

Group Art Unit No.: Not Yet Assigned

Filed:

Herewith

Examiner: Not Yet Assigned

For:

TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN

SECRETAGOGUE AND DIGUANIDE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

Attorney for Applicants

Registration No. 40,072

**GLAXOSMITHKLINE** Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5012 Facsimile (610) 270-5090 N:\kls\cases\p31853c2\IDS Letter.doc

<u></u>				T . = . = . = =			<u>neet 1 (</u>	of <u>1</u> .		
Form PTO-		partment of Comm nt and Trademark C		ATTY. DOCKET NO. P31853C2  SERIAL NO. Not Yet Assigned						
INFORMATION DISCLOSURE STATEMENT			APPLICANT							
	BY APPLICA		Buckingham, et al							
				FILING DATE		GROUP		-		
	(Use several sheets if	necessary)		Herewith	•	Not Yet As	ssigned			
		U.S. PA	TENT	DOCUMENTS						
Examiner Initial	Document	Date		Name	Class	1 9				
II IIIIQI	Number		<del></del> -				If Appi	ropriate		
					<del></del>					
		<del>                                     </del>	_							
	·	<del>                                     </del>								
		<del>                                     </del>								
						_				
		1								
1		FOREIGN	PATE	NT DOCUMENTS						
	Document	Date		Country Class		Subclass		slation		
-	Number					Class Subclass <u>Trar</u> Yes				
		ļ:						<del> </del>		
		-		<del></del>						
								-		
					<del></del>			-		
					<u> </u>			-		
								<u> </u>		
				hor, Title, Date, Pertine		tc.)				
ļļ.				ebsite – www.pdrhe						
				armacol., <u>54</u> : 169-1						
				n Therapy of Trogli						
	-	_		ere Poorly Controlle	ed By Sulp	honylurea T	herapy			
		ic Medicine, 13: 3								
				e Management of N			Diabet	es		
				petic Medicine, 11:						
Nakano, et al., "Clinical Evaluation of Profile of Blood Glucose in Patients w				a New Oral Hypogl	lycemic Dr	ug, CS-045,	on Dai	ily		
							tus".			
	Kinsyou Iyaku (	Cunical Medicine	), <u>9th</u>	Vol., Supp. 3: pp.	151-164 (1	993).				
				<u> </u>	<del></del>					
EXAMINER				DATE CONSIDERED						
I EVWINIINEK				DATE CONSIDERED						
EXAMINER	: Initial if citation consider	ered, whether or no	t citat	ion is in conformance	with MPEP 6	009; Draw line	through	h .		
n:\kls\case	not in conformance and s\p31853c2\pto 1449 form.	nor considered. Inc	ciude :	copyot this form with i	next commu	inication to a	pplican	it.		

Sheet 1 of 2

Form PTO-1449	U.S. Department of Commerce	ATTY, DOCKET NO.	PRED. SERIAL NO.
	Patent and Trademark Office	P31853C2	09/939,470
	•		
INFORMATIO	N DISCLOSURE STATEMENT	APPLICANT	
		Buckingham, et al.	
	BY APPLICANT	Zuomangham, or an	
		PRED. FILING DATE	PRED. GROUP ART UNIT
(Use sev	veral sheets if necessary)	August 24, 2001	1617
	·	l	

## **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	6,153,632	11/28/00	Rieveley	514	369	
	6,271,243	8/7/01	Ikeda, et al.	514	342	
	5,965,584	10/12/99	Ikeda, et al.	514	342	
	6,150,383	11/21/00	Ikeda, et al.	514	342	
	6,031,004	2/29/00	Timmins, et al.	514	635	
	5,952,356	9/14/99	Ikeda, et al.	514	340	
	6,291,495	9/18/01	Rieveley	514	369	
	5,900,435	5/4/99	Martin D. Meglasson	514	565	

# FOREIGN PATENT DOCUMENTS

	Document	Date	Country	Class	Subclass	Trans	lation
	Number					Yes	No
	WO 97/17975	5/22/97	PCT				
3	WO 98/36755	8/1998	PCT				
	0 861 666 A2	9/1998	EPO				
	WO 95/21608	8/1995	PCT				
	0 749 751	12/1996	EPO				
	WO 93/03724	3/1993	PCT				
	WO 96/09823	4/1996	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.)
Weinstock, et al., "Pioglitazone: In Vitro Effects on Rap Hepatoma Cells and In Vivo Liver
Hypertrophy in KKA <sup>y</sup> Mice". <i>Pharmacology</i> , <u>54</u> : 169-178 (1997).
Hofmann, et al., "New Oral Thiazolidinedione Antidiabetic Agents Act as Insulin Sensitizers".
Diabetes Care, <u>15(8)</u> : 1075-1078 (1992).
Foot, et al., "Improved Metabolic Control by Addition of Troglitazone to Glibenclamide Therapy in
Non-Insulin Dependent Diabetics". Diabetologia, 38(S1): A44 (1995).
Whitcomb, et al., "Thiazolidinediones". Exp. Opin. Invest. Drugs, 4(12): 1299-1309 (1995).
Inzucchi, et al., "Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes
Mellitus". New England Journal of Medicine, <u>338(13)</u> : 867-872 (1998).
Ishida, et al., "Oral Hypoglycemic Agents - New Oral Drugs and New Strategy of Treatment". Clinic
All-Round, <u>43</u> : 2615-2621 (1994).
Hermann, et al., "Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various
Combinations". <i>Diabetes Care</i> , <u>17(10)</u> : 1100-1109 (1994).
Haupt, et al., "Oral Antidiabetic Combination Therapy with Sulphonylureas and Metformin". Diabete
& Metabolisme, <u>17</u> : 224-231 (1991).
Scheen, et al., "Oral Antidiabetic Agents". Drugs, 55(2): 225-236 (1998).
DATE CONSIDERED

Sheet 2 of 2.

Form PTO-1449  U.S. Department of Comm Patent and Trademark C		SERIAL NO. 09/939,470
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Buckingham, et al.	
(Use several sheets if necessary)	FILING DATE August 24, 2001	GROUP 1617

## **U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	4,895,862	1/23/90	Alessi, et al.	514	360	, , , , , , , , , , , ,
	5,068,342	11/26/91	Zask, et al.	548	183	

## FOREIGN PATENT DOCUMENTS

Document	Date	Country	Class	Subclass	<u>Trans</u> l	lation
Number					Yes	No
						,

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	GITTER DOGGITETTO (including 7 tarrior, time, bare, 1 crimerit 1 ages, 21c.)
	Iwamoto, et al., "Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin
	Secretion in Patients with NIDDM". Diabetes Care, 14(11): 1083-1086 (1991).
	Hotta. Tonyobyo, Update 10: 68-77 (1994) (with translation).
	Hotta. Chronic Disease, 6(1):1-9 (1995) (with translation).
	Cusi, et al., "Metoformin: A Review of its Metabolic Effects". Diabetes Review, 6(2): 89-131 (1998).
	Arshag D. Mooradian. "Drug Therapy of Non-Insulin-Dependent Diabetes Mellitus in the Elderly". <i>Drugs</i> , 51(6): 931-941 (1996).
	K. Doi. "New Oral Hypoglycemic Agents and Hypoglycemic Agents Under Development". <i>J. Japan Diabetes Science</i> , 3(Suppl. 1): 962-973 (1990) (with translation).
	Kelley, et al., "Troglitazone". Current Opinion in Endocrinology and Diabetes, 5(2): 90-96 (1998).
	A.J. Scheen. "Drug Treatment of Non-Insulin-Dependent Diabetes Mellitus in the 1990s. Achievements and Future Developments". <i>Drugs</i> , <u>54(3)</u> : 355-368 (1997).
	Windholz, et al. The Merck Index, 10th Edition: 635, Abstract Nos. 4300 & 4302 (1983).
	H. Lebovitz. "Stepwise and Combination Drug Therapy for the Treatment of NIDDM". <i>Diabetes Care</i> , 17(12): 1542-1544 (1994).
	Lehmann, et al., "An Antidiabetic Thiazolidinedione is a High Affinity Ligand for Peroxisome Proliferator-Activated Receptor γ (PPARγ)". <i>The Journal of Biological Chemistry</i> , <u>270</u> : 12953-12956 (1995).
	Donnelly, et al., "Drugs and Insulin Resistance: Clinical Methods of Evaluation and New Pharmacological Approaches to Metabolism". <i>Br. J. Clin. Pharmacol.</i> , 37: 311-320 (1994).
	Jackson, et al., "Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes". <i>Diabetes</i> , <u>36</u> : 632-640 (1987).
	Williams, et al., "Management of Non-Insulin-Dependent Diabetes Mellitus". <i>The Lancet</i> , <u>343</u> : 95-100 (1994).
	Kappel, et al., "Type 2 Diabetes: Update on Therapy", (1998), <i>Comprehensive Therapy</i> , <u>24(6-7)</u> , pp. 319-326 (XP002080974).
	Elson, et al., "Therapy for Type 2 Diabetes Mellitus", (1998), Wisconsin Medical Journal, 97(3): 49-54 (XP002081122).
	Wolffenbuttel, et al., "New Treatments for Patients with Type 2 Diabetes Mellitus", (1995), <i>Postgrad. Med. J.</i> , 72: 657-662.
	DATE CONSIDERED
1	

n:\kls\cases\p31853c2\prior art 1449 form.doc